



## **Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow**

November 5, 2018

ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its third quarter 2018 financial results will be released at approximately 7:00 a.m. ET on Thursday, November 8, 2018. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss its financial results and provide a general business and strategic review.

The live webcast and a replay may be accessed by visiting the "Investor Relations" section at [www.clearsidebio.com](http://www.clearsidebio.com). Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to participate in the live conference call. The conference ID number for the live call is 4634909. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until February 9, 2019.

### **About Clearside**

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside's proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company's unique platform for eye disease treatments is inherently flexible and intended to work with established medicines, new formulations of medicines, as well as future innovations. Clearside's pipeline includes advanced and pre-clinical product candidates in diseases where macular edema is a common complication, including uveitis and diabetic macular edema ("DME"). Clearside's most advanced program is in non-infectious uveitis and it expects to submit a NDA to the FDA for XIPERE for the treatment of uveitic macular edema by the end of 2018. In addition, Clearside recently announced positive topline results from a Phase 2 clinical trial of XIPERE used with EYLEA® (afibercept) in patients with DME. Clearside is headquartered in Alpharetta, GA. For more information, please visit <http://www.clearsidebio.com>. Follow @clearsidebio on Twitter and LinkedIn.

### **Contacts:**

Stephen Kilmer  
Investor Relations  
(678) 430-8206  
[stephen.kilmer@clearsidebio.com](mailto:stephen.kilmer@clearsidebio.com)

Charles Deignan  
Chief Financial Officer  
(678) 270-4005  
[charlie.deignan@clearsidebio.com](mailto:charlie.deignan@clearsidebio.com)



Source: Clearside Biomedical, Inc.